The Disparity in Access to New Medication by Type of Health Insurance

Lessons From Germany

Datos Bibliográficos

ID9104463
AutoresKarl J Krobot (University of North Carolina at Chapel Hill, autor de correspondencia), William C Miller (0000-0003-3060-0210, University of North Carolina at Chapel Hill, autor de correspondencia), Jay S Kaufman (0000-0003-1606-401X, University of North Carolina at Chapel Hill, autor de correspondencia), Dale B Christensen (University of North Carolina at Chapel Hill), John S Preisser (0000-0002-7869-2057, University of North Carolina at Chapel Hill), Michel A Ibrahim, Michel Ibrahim (0000-0001-9624-0698, University of North Carolina at Chapel Hill, autor de correspondencia)
Año2004
Volumen42
Número5
Páginas487-491
Fecha de publicación2004-05-01
Peer ReviewedSí
Open AccessNo
TipoARTICLE
RevistaMedical Care (JOURNAL)
Identificadores de la revistaISSN: 0025-7079 • E-ISSN: 1537-1948
EditorialOvid Technologies (Wolters Kluwer Health) (PUBLISHER)
DOI10.1097/01.mlr.0000124265.13559.02
PMID15083110
OpenAlexW2058166221
IdiomaEN
Citas recibidas5
Referencias citadas15

BACKGROUND: Drug provision within the German statutory health insurance system has undergone several reforms, including the introduction of drug macrobudgets in 1993. OBJECTIVE: The objective of this study was to investigate the extent to which statutorily (SHI) and fully privately (PHI) health-insured patients were provided with new medication recommended by professional bodies in an equitable fashion using the example of migraine patients. RESEARCH DESIGN: We conducted a retrospective cohort study. SETTING: A total of 367 primary-care practices (MediPlus, IMS Health) in Germany in the second year of the HealthCare Structural Reform Act were studied. SUBJECTS: Subjected consisted of 7703 SHI and 470 PHI migraineurs (International Classification of Diseases, 10th edition G43) aged 18 to 65 years at their first migraine prescription visit in 1994. OUTCOME MEASURE: We compared prescription of oral or subcutaneous serotonin 5HT1B/1D receptor agonist sumatriptan with nonserotoninergic migraine therapy. RESULTS: In multiplicative risk regression with variance estimation accounting for clustering of patients within practices, PHI patients were 2.3 times (95% confidence interval [CI], 1.6-3.3) more likely to receive sumatriptan than their SHI counterparts at the mean age of the cohorts (43 years) adjusted for incident versus prevalent migraine treatment, the gender of the patient, the age, gender, and primary care specialist group of the physician, and the type and the community size class of the practice. This disparity widened by 38% (95% CI, 1-88%) every 10 years of patient age. CONCLUSION: Even though virtually everyone in Germany has health insurance and drug coverage, use of new and recommended migraine medicines was less common among those with SHI compared with their privately insured counterparts. Systematic studies of access to health care recommended by professional bodies will be critically important to ensure delivery of high-quality health care for all patients

Agonist · Confidence interval · Family medicine · Health care · Medical prescription · Migraine · Psychiatry · Sumatriptan · Demography · Health and Medical Studies · Internal Medicine · Medication Adherence and Compliance · Medicine · Migraine and Headache Studies · Nursing · Pediatrics